129112-65-8

Basic information

• Product Name: 2,4-dichloro-7-nitroquinazoline
• Synonyms: 2,4-dichloro-7-nitroquinazoline
• CAS NO: 129112-65-8
• Molecular Weight: 244.037
• Mol File: 129112-65-8.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: 2,4-dichloro-7-nitroquinazoline(CAS DataBase Reference)
• NIST Chemistry Reference: 2,4-dichloro-7-nitroquinazoline(129112-65-8)
• EPA Substance Registry System: 2,4-dichloro-7-nitroquinazoline(129112-65-8)

Safety Data

• Hazardous Substances Data: 129112-65-8(Hazardous Substances Data)

Usage

Description

2,4-dichloro-7-nitroquinazoline is an organic compound that serves as a crucial intermediate in the synthesis of various pharmaceutical agents. It is characterized by its chemical structure, which includes two chlorine atoms at the 2nd and 4th positions, and a nitro group at the 7th position of the quinazoline ring. 2,4-dichloro-7-nitroquinazoline plays a significant role in the development of therapeutic drugs due to its unique properties and reactivity.

Uses

Used in Pharmaceutical Industry:
2,4-dichloro-7-nitroquinazoline is used as a key intermediate for the synthesis of 4-phenoxy-2-(1-piperazinyl)quinazolines. These quinazoline derivatives exhibit potent anticonvulsive and antihypoxic properties, making them valuable in the treatment of seizures and hypoxic conditions. The compound's ability to form these therapeutic agents highlights its importance in the development of new medications for neurological disorders.
Additionally, 2,4-dichloro-7-nitroquinazoline is used to prepare quinazoline-based stem cell mobilizers that target the chemokine receptor CXCR4. These mobilizers play a crucial role in the field of regenerative medicine, as they can potentially enhance the migration and homing of stem cells to damaged tissues, promoting tissue repair and regeneration.

Upstream product

• 2879-79-0 N-(2-methyl-5-nitrophenyl)acetamide 
• 951-97-3 2-acetamido-4-nitrobenzoic acid 
• 619-17-0 4-Nitroanthranilic acid 
• 174565-63-0 7-nitro-1,2,3,4-tetrahydro-quinazoline-2,4-dione 

Downstream Products

• 129112-48-7 2-(4-Methyl-piperazin-1-yl)-7-nitro-4-phenoxy-quinazoline 
• 129112-50-1 2-(4-Methyl-piperazin-1-yl)-4-phenoxy-quinazolin-7-ylamine 
• 129112-52-3 7-Chloro-2-(4-methyl-piperazin-1-yl)-4-phenoxy-quinazoline 
• 76004-97-2 N²-(3,4-dichlorophenyl)-N⁴-<2-(diethylamino)ethyl>-7-nitro-2,4-quinazolinediamine 1.8-hydrochloride 
• 129112-64-7 2-Chloro-7-nitro-4(3H)-quinazolinone 

Relevant articles and documents

INHIBITORS OF CYCLIN-DEPENDENT KINASES

Provided herein are compounds which are inhibitors of cyclin-dependent kinases (CDKs), pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.

DIACYLGLYCEROL KINASE MODULATING COMPOUNDS

The present disclosure provides diacylglycerol kinase modulating compounds, and pharmaceutical compositions thereof, for treating cancer, including solid tumors, and viral infections, such as HIV or hepatitis B virus infection. The compounds can be used alone or in combination with other agents.

Tricyclic dicarbonyl derivatives

Compounds of general formula (Ia), (Ib) and (II), wherein R1 and R2 each independently signify hydrogen, lower alkyl, lower alkoxy, nitro, trifluoromethyl, amino, halogen, cyano or R3 R4 NS(O)2 -- and R3 and R4 signify lower alkyl, and R2 can additionally signify morpholino or thiomorpholino, a 5- or 6-membered heterocycle with 1-3N atoms optionally substituted by lower alkyl, hydroxy, amino or the group --CH2 NHCH3, a bicyclic heterocycle with 1-3N atoms or a group --NR5 R6 or --OR5 in which R5 and R6 can be the same or different and signify hydrogen, lower alkyl, hydroxy-lower alkyl, lower alkoxy-lower alkyl, amino-lower alkyl or lower alkylamino-lower alkyl, and X in formula (II) signifies --CH=CH--, --CH=N--, --NH--, --CO-- or --O--, as well as pharmaceutically usable salts of compounds of general formula (Ia), (Ib) and (II). They can be used for the treatment or prevention of illnesses, especially for the treatment or prevention of ischemia, hypoglycaemia, hypoxia, cerebral vascular spasms, spasticity, trauma, hemorrhagia, infection (viral, bacterial, amoebic, prional), epileptic seizures, autoimmune diseases, withdrawal symptoms, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, Huntington's disease, intoxications, olivoponto-cerebellar atrophy, spinal cord injuries, schizophrenia, depressions, anxiety states, dependence, pains,autism and mental retardation.